Bank of milan

The most advanced product candidate has completed pivotal clinical studies and an application for market authorization has been submitted to the US FDA earlier this year. All bank of milan LifeCycle Pharmas product candidates are based on the companys MeltDose technology, which is particularly suited to create new and improved versions of existing drugs.

By applying the MeltDose technology to improve the efficacy of well-known and valuable drugs, we believe that we are able to develop products significantly faster and cheaper and with a higher success miilan compared to the development of completely new drugs.

Bank of milan – opinion

The most advanced product candidate has completed pivotal clinical studies and an application for market authorization has been submitted to the US FDA earlier this year. All of LifeCycle Pharmas product candidates are based on the companys MeltDose technology, which is particularly suited to bank of milan new and improved versions of existing drugs. By applying the MeltDose technology to improve the efficacy of well-known and valuable drugs, we believe that we are able to develop products significantly faster and cheaper and with mian higher success rate compared to the development of completely new drugs.

The company has a bank of milan product pipeline with a portfolio of six proprietary product candidates in clinical development. The most advanced product candidate has completed pivotal clinical studies and an application for milna authorization has been submitted to the US FDA earlier this year. All of LifeCycle Pharmas product candidates are based on the companys MeltDose technology, which is particularly suited to create new and improved versions of existing drugs.